Stockscreener 앱 받기
272.89
1.09%
2.94
시간 외 거래:
272.89
전일 마감가:
$269.95
열려 있는:
$266.88
하루 거래량:
1.53M
Relative Volume:
0.97
시가총액:
$39.08B
수익:
$2.50B
순이익/손실:
$-226.32M
주가수익비율:
-166.27
EPS:
-1.6412
순현금흐름:
$71.51M
1주 성능:
-3.84%
1개월 성능:
+28.68%
6개월 성능:
+14.71%
1년 성능:
+70.10%
1일 변동 폭
$261.63
$273.33
1주일 범위
$261.63
$287.63
52주 변동 폭
$131.81
$288.04
Natera Inc Stock (NTRA) Company Profile
명칭
Natera Inc
전화
650-249-9090
주소
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
272.89 | 38.66B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
528.51 | 195.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
200.16 | 140.88B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
564.21 | 44.46B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
134.04 | 37.93B | 7.23B | 1.41B | 1.09B | 4.979 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | William Blair | Outperform |
| 2026-01-07 | 개시 | Citigroup | Buy |
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-10-27 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | 재개 | Wells Fargo | Equal Weight |
| 2025-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-08 | 재개 | Craig Hallum | Buy |
| 2024-02-20 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-11-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 개시 | Stephens | Overweight |
| 2022-03-08 | 개시 | Goldman | Buy |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-09-28 | 개시 | Morgan Stanley | Overweight |
| 2020-09-17 | 개시 | SVB Leerink | Outperform |
| 2020-06-10 | 재개 | Piper Sandler | Overweight |
| 2020-05-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 개시 | JP Morgan | Neutral |
| 2018-07-05 | 재확인 | Piper Jaffray | Overweight |
| 2017-08-07 | 재확인 | Morgan Stanley | Overweight |
| 2016-11-10 | 재확인 | The Benchmark Company | Buy |
| 2016-05-23 | 재확인 | The Benchmark Company | Buy |
| 2016-05-11 | 재확인 | The Benchmark Company | Buy |
| 2016-04-19 | 개시 | The Benchmark Company | Buy |
| 2015-09-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2015-08-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 개시 | Robert W. Baird | Outperform |
| 2015-07-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 개시 | Piper Jaffray | Overweight |
| 2015-07-27 | 개시 | Wedbush | Neutral |
모두보기
Natera Inc 주식(NTRA)의 최신 뉴스
Enterprise value to EBITDA forward of Natera, Inc. – BX:NTRA - TradingView
[144] Natera, Inc. SEC Filing - Stock Titan
Enterprise value to EBITDA forward of Natera, Inc. – XETR:45E - TradingView
Did EU Class C Status for Signatera Reshape Natera’s (NTRA) Long-Term Diagnostics Strategy? - Yahoo Finance
What's Driving Natera's Recent Stock Action and Insider Selling - Kavout | AI
Is Natera (NTRA) Fully Valued As Signatera Wins EU IVDR Certification? - simplywall.st
Natera (NTRA) Secures EU Certification, Is The Upside Already Priced In? - Yahoo Finance
Why Natera (NTRA) Stock Is Down Today - Quiver Quantitative
Natera (NTRA) Signatera Data Shows Who Benefits From Chemotherapy After CRC Surgery - Yahoo Finance
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers - Yahoo Finance
Natera (NTRA) Stock Still Looks Expensive After A Very Large Run - Yahoo Finance
NTRA Maintained by Morgan Stanley -- Price Target Raised to $310 - GuruFocus
Morgan Stanley Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $310 - Moomoo
Natera, Inc. Stock 12‑Month Price Target Raised to $272.19, Implies 1% Downside - TradingView
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers - 01net
How New Signatera Colorectal Data and Trial Deals Could Shape Natera’s (NTRA) Long-Term Narrative - simplywall.st
Natera’s Signatera receives EU IVDR certification for MRD testing By Investing.com - Investing.com South Africa
Natera’s Signatera receives EU IVDR certification for MRD testing - Investing.com
Natera Receives EU IVDR Certification for Signatera - Moomoo
Natera (NTRA) Achieves Significant Milestone with Signatera IVDR Certification - GuruFocus
Natera's Insider Selling Spree: A Red Flag Amidst Robust Growth - Kavout | AI
Natera executive chairman Matthew Rabinowitz sells $280,000 in shares By Investing.com - Investing.com Nigeria
Natera executive chairman Matthew Rabinowitz sells $280,000 in shares - Investing.com
(NTRA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Form 4 Natera Inc For: 8 July By Investing.com - Investing.com Nigeria
Natera (NTRA) executive chair’s spouse sells 1,000 shares in pre‑planned trade - Stock Titan
Form 4 Natera Inc For: 6 July By Investing.com - Investing.com India
Natera president Solomon Moshkevich sells $818,710 in stock - Investing.com UK
Natera chief legal officer Daniel Rabinowitz sells $4.57m stock - Investing.com
Natera chief legal officer Daniel Rabinowitz sells $4.57m stock By Investing.com - Investing.com Australia
Natera | 4: Statement of changes in beneficial ownership of securities-Director Rubin Eric H - Moomoo
Natera president Solomon Moshkevich sells $818,710 in stock By Investing.com - Investing.com Australia
Natera (NTRA) president sells 3,000 shares under Rule 10b5-1 trading plan - Stock Titan
Natera (NTRA) legal chief sells 16,800 shares under Rule 10b5-1 plan - Stock Titan
Form 144 NATERA For: 6 July By Investing.com - Investing.com South Africa
Natera study shows MRD test predicts chemo benefit in liver cancer - Investing.com UK
Matthew Rabinowitz sells 50,000 shares — (NASDAQ: NTRA) - Stock Titan
Board member Monica Bertagnolli exits Natera (NASDAQ: NTRA) - Stock Titan
Natera study shows MRD test predicts chemo benefit in liver cancer By Investing.com - Investing.com South Africa
Natera demonstrates MRD test benefit in colorectal cancer patients - Medical Device Network
Natera publishes Signatera survival data in JAMA Oncology - grafa.com
Evercore Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $300 - Moomoo
Natera (NTRA) Gains Insight into Colorectal Cancer Treatment Out - GuruFocus
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer - Yahoo Finance
Natera, Inc. (NTRA) Stock Analysis: Navigating Growth Amidst Challenging Valuations - DirectorsTalk Interviews
Natera Q1 2026 slides: revenue jumps 39%, guidance raised - Investing.com
3 Healthcare Stocks Built For Higher Rates And Steady Demand - Sahm
Natera Inc focuses on genetic testing growth as investors watch Nasdaq trading - AD HOC NEWS
Natera (NTRA) Lands New Trial Partnerships, Is The Upside Already Priced In? - simplywall.st
NTRANatera Inc Options - Finviz
Natera stock hits all-time high at $279.63 By Investing.com - Investing.com South Africa
Natera Inc (NTRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Natera Inc 주식 (NTRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER |
Jul 01 '26 |
Sale |
272.29 |
16,800 |
4,574,431 |
172,294 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Jul 01 '26 |
Sale |
272.90 |
3,000 |
818,710 |
134,643 |
0.19%
0.11%
자본화:
|
볼륨(24시간):